Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)

Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Mylan N.V. MYL , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in MYL.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen six estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from $5.24 a share a month ago to its current level of $4.56.

Also, for the current quarter, Mylan has seen five downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to $1.20 a share from $1.45 over the past 30 days.  

The stock also has seen some pretty dismal trading lately, as the share price has dropped 23.5% in the past month.

Mylan N.V. Price and Consensus

Mylan N.V. Price and Consensus | Mylan N.V. Quote

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Health Care sector, you may instead consider a better-ranked stock – Gilead Sciences, Inc. GILD . The stock currently holds a Zacks Rank #2 (Buy) and may be a better selection at this time. You can see  the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it’s predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce “the world’s first trillionaires,” but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks’ 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Mylan N.V. (MYL): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Related posts